Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 for drug discovery and mechanism of action (MOA) research

Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). Patients with haemophilia B lack factor IX, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The albutrepenonacog alfa, works in the body in the same way as human factor IX and replaces the missing factor IX, thereby helping the blood to clot and giving temporary control of bleeding.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-726-1mg	1mg	3090
GMP-Bios-INN-726-10mg	10mg	Inquiry
GMP-Bios-INN-726-100mg	100mg	Inquiry
GMP-Bios-INN-726-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
INN Name	Albutrepenonacog Alfa
Target	F9
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - F9 (coagulation factor 9, coagulation factor IX) recombinant - ALB (albumin, human serum albumin, HSA) 25-609
VD LC	Fusion - F9 (coagulation factor 9, coagulation factor IX) recombinant - ALB (albumin, human serum albumin, HSA) 25-609
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	CSL Behring (King of Prussia PA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0